Polyrizon Completes Enrollment of 120 Patients in U.S. NASARIX Study
All 120 planned participants were randomized across five U.S. clinical sites in the study of the NASARIX allergy blocker.
All 120 planned participants were randomized across five U.S. clinical sites in the study of the NASARIX allergy blocker.